leuven research institute for neurodegenerative disorders · motor neuron diseases, and secondary...

of 108/108
Leuven research Institute for Neurodegenerative Disorders

Post on 25-Jan-2019

231 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

Leuven research

Institute for

Neurodegenerative

Disorders

Citation: LIND (2011) Brochure: Leuven research Institute for Neurodegenerative Disorders,

www.kuleuven.be/samenwerking/lind

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

1

TABLE OF CONTENTS

Introduction ............................................................................................................................................. 3

Structure of LIND ................................................................................................................................. 4

Mode of operation of LIND ................................................................................................................. 6

Executive Board ....................................................................................................................................... 7

Bart De Strooper, M.D., Ph.D. ............................................................................................................. 7

Wim Robberecht, M.D., Ph.D. ........................................................................................................... 10

Steering Committee members .............................................................................................................. 13

Veerle Baekelandt, Ph.D. ................................................................................................................... 13

Peter Carmeliet, M.D., Ph.D. ............................................................................................................. 16

Rudi DHooge, Ph.D. .......................................................................................................................... 18

Peter Janssen, M.D., Ph.D. ................................................................................................................ 21

Stefan Sunaert, M.D., Ph.D. ............................................................................................................... 23

Koen Van Laere, M.D., Ph.D., D.Sc. ................................................................................................... 26

Rik Vandenberghe, M.D., Ph.D. ......................................................................................................... 28

Patrik Verstreken, Ph.D. .................................................................................................................... 31

Members ............................................................................................................................................... 33

Wim Annaert, Ph.D. ........................................................................................................................... 33

Steven Boonen, M.D., Ph.D. .............................................................................................................. 36

Jan De Lepeleire, M.D., Ph.D. ............................................................................................................ 38

Bert De Smedt, Ph.D. ......................................................................................................................... 41

Anja Declercq, Ph.D. .......................................................................................................................... 43

Carlos Dotti, M.D., Ph.D ..................................................................................................................... 46

Bndicte Dubois, M.D., Ph.D. .......................................................................................................... 49

Wolfgang Eberle, Ph.D. ...................................................................................................................... 51

Yves Engelborghs, Ph.D. .................................................................................................................... 53

An Goris, Ph.D. ................................................................................................................................... 55

Ann Heylighen, Ph.D. ......................................................................................................................... 57

Bea Maes, Ph.D.................................................................................................................................. 60

Gert Matthijs, Ph.D. ........................................................................................................................... 63

Lieve Moons, Ph.D. ............................................................................................................................ 65

Alice Nieuwboer, Ph.D. ...................................................................................................................... 68

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

2

Ilse Noens, Ph.D. ................................................................................................................................ 70

Herman Nys, Ph.D. ............................................................................................................................ 72

Anton Roebroek, Ph.D. ...................................................................................................................... 74

Birgitte Schoenmakers, M.D., Ph.D. .................................................................................................. 76

Raf Sciot M.D., Ph.D........................................................................................................................... 78

Nele Spruytte, Ph.D. .......................................................................................................................... 79

Stephan Swinnen, Ph.D. .................................................................................................................... 81

Johan Thevelein, Ph.D. ...................................................................................................................... 83

Vincent Thijs, M.D., Ph.D. .................................................................................................................. 85

Jos Tournoy, M.D., Ph.D. ................................................................................................................... 87

Thomas Tousseyn, M.D., Ph.D. .......................................................................................................... 89

Chantal Van Audenhove, Ph.D. ......................................................................................................... 92

Philip Van Damme, M.D., Ph.D. ......................................................................................................... 95

Ludo Van Den Bosch, Ph.D. ............................................................................................................... 98

Pieter Vanden Berghe, Ph.D. ........................................................................................................... 100

Wim Vandenberghe, M.D., Ph.D. .................................................................................................... 103

Joris Winderickx, Ph.D ..................................................................................................................... 105

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

3

INTRODUCTION

The main objective of the Leuven research Institute for Neurodegenerative Disorders (LIND) is to

stimulate interactions between the different research groups working on these diseases at the

K.U.Leuven and to promote and accelerate the development of diagnostic and therapeutic strategies

for these diseases.

Improvements in medical care and hygiene in the

last century have indeed caused a dramatic increase in

average life expectancy throughout the world. Age-

related neurodegenerative disorders represent now

more than ever a major biomedical challenge and an

enormous burden for health care systems.

For instance, different forms of age associated

dementia are estimated to presently affect 35.6 million

people worldwide (Alzheimers Disease International)

and 5.3 to 5.8 million people in the European Union (Alzheimer Europe) alone. Due to the increasing

life expectancy, the number of affected people in the European Union is expected to triple to 15.9

million by 2040, when about approximately 24% of the total population in Europe will be older than

65 years (http://www.iiasa.ac.at/Research/ERD/DB/data/hum/dem/dem_2.htm).

The societal costs of dementia in Europe are enormous and greatly affect the health care and

social systems. The total societal costs of dementia in Europe are estimated to 103 billion , with an

average annual costs per patient of 12000 (Alzheimer Europe).

Given the expected dramatic increase in the incidence of age-related neurodegenerative

disorders worldwide and the extreme burden put on the health care system, it is clear that finding a

treatment for these disorders, aimed at maintaining quality of life and independence for patients and

their families, is a highly prioritized and major scientific and social task. This aim can only be

accomplished by multidisciplinary translational research. A recent editorial in Nature stressed the

importance of translational research and interactions between clinicians and fundamental

researchers (Hope in translation Nature 467, page 499, 2010).

LIND will therefore bundle on a voluntary basis all interested fundamental and clinical

research groups at the K.U.Leuven that perform studies related to neurodegenerative disorders. LIND

will provide a platform for regular discussions between these research groups and the K.U.Leuven,

VIB and UZ Leuven and will stimulate the internal communication, and

encourage novel and otherwise unexplored collaborations. Given the

worldwide tendency to bundle efforts in this research area in dedicated

institutes (e.g. the Deutches Zentrum fr Neurodegenerative

Erkrankungen (DZNE) in Germany), such bundling of efforts in Leuven

appears indeed crucial to maintain our international competitive

position. We intend to partner with European networks for research into

aging and neurodegenerative disorders and with companies interested

in our fundamental and clinical work. We hope to identify strengths and

to remedy weaknesses in our research structure and to bring the

different stake holders together to take common initiatives and to

coordinate efforts. We are convinced that the available expertise at the

http://www.iiasa.ac.at/Research/ERD/DB/data/hum/dem/dem_2.htm

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

4

K.U.Leuven is broad and excellent and provides the

basis to develop LIND into a European center of

excellence.

In addition, LIND will act as an easy

accessible point of reference and expertise for

academic and governmental authorities interested

in neurodegenerative diseases. The institute will

lobby with the Flemish and the Belgian

governments to promote research into these

devastating disorders and to accelerate the

development of therapeutics.

As a center of excellence, LIND will also offer its expertise and help for the recruitment of

young investigators in this domain of research. Finally, LIND will provide the means to apply in a

coordinated way to major initiatives for funding of research in this domain of investigation (e.g. FET-

flagships).

STRUCTURE OF LIND

LIND will be directed by a general assembly consisting of all participating senior investigators of the

K.U.Leuven, VIB-Leuven and UZ Leuven. The leadership structure of LIND includes a strategic advisory

board, steering committee and an executive board (Fig. 1).

The following persons will be asked to reside in the strategic advisory board of the institute:

The rector of the K.U.Leuven, Mark Waer

The vice rector of Biomedical Sciences Group, Minne Casteels

The vice rector of Humanities and Social Sciences Group, Filip Abraham

The vice rector of Science, Engineering and Technology Group, Karen Maex

The vice rector of Research Policy, Peter Marynen

The vice rector International Policy, Bart De Moor

The general director of Technology Transfer, Paul Van Dun

The chairman of the steering committee UZ Leuven, Guy Mannaerts

The chairman of the executive committee UZ Leuven, Johan Kips

The chairman of the medical board UZ Leuven, Dirk Vlasselaers

The directors of the Flanders Institute for Biotechnology (VIB), Jo Bury and Rudy Dekeyser

The task of the strategic advisory board is to provide positive stimuli to the initiative, to critically

evaluate its work and to follow up on the progress of LIND. The strategic advisory board will receive

yearly a report on the progress of the institute.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

5

Figure 1: Structure of LIND. (ARCK: Alzheimer Research Center K.U.Leuven, ND: Neurodegenerative

Diseases)

The steering committee will be composed of scientists from various key research areas related to

neurodegenerative diseases. The following members are proposed for the steering committee:

Prof. Veerle Baekelandt as expert in Parkinsons disease

Prof. Peter Carmeliet as expert on ALS and director of Vesalius Research Center (VRC)

Prof. Rudi DHooge as expert in preclinical studies on pathophysiology and treatment of

neurodegeneration and use of rodent models for these diseases

Prof. Peter Janssen as expert in neurophysiology

Prof. Stefan Sunaert as expert in radiology

Prof. Koen Van Laere as expert in nuclear imaging

Prof. Rik Vandenberghe as expert in clinical treatment of patients with cortical

neurodegenerative diseases and director of the Alzheimers Research Center K.U.Leuven

(ARCK)

Prof. Patrik Verstreken as expert in synapse biology and Parkinson Disease

Prof. Bart De Strooper as specialist in Alzheimers disease and as contact person with the

brain research center Neuroelectronics Research Flanders (NERF)

Prof. Wim Robberecht as head of the neurological clinic and translational research in ALS

Theme leaders, who will be appointed in a later stadium

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

6

The executive board of LIND will be composed of founding director, Prof Bart De Strooper, and

founding co-director, Prof. Wim Robberecht. They will be supported by the coordinator, Dr. Griet

Holsbeek, who will assist them in managing the daily administration of the institute.

MODE OF OPERATION OF LIND

LIND will focus its research on four main themes: cortical neurodegenerative diseases (Alzheimers

disease and frontotemporal degeneration ARCK), movement disorders (e.g. Parkinsons disease),

motor neuron diseases, and secondary neurodegeneration (i.e. induced by secondary causes, such as

epilepsy, inflammation, etc.). One theme to be added in the future is social, economical and ethical

aspects of these diseases. Other themes can be included by the steering committee as appropriate.

The executive board will be responsible to kick off the initiative by calling together all

interested research groups at K.U.Leuven. They will make an inventory of the available expertise and

strengths. The institute will invite all interested scientists belonging to the various research domains,

such as clinical research, basic research, neurogenetics, neuropathology, imaging, social sciences. The

executive board will meet regularly to discuss the operation of the institute and agree upon future

actions to promote the working of the institute. Next to organizing meetings and congresses, an

important task of LIND will be to invite an external scientific advisory committee (SAC) consisting of

international renowned academicians, clinicians and industrial opinion leaders in the field of aging

and neurodegeneration to assist and advise the steering committee with its scientific and managerial

strategies. The contributing groups will assess on a regular basis strengths and weaknesses in the

institute and will cooperate to strengthen the scientific backbone of the institute. The SAC-report will

be a help and a support in this endeavor and its results will be submitted to the strategic advisory

board.

Finally, LIND will be used to increase awareness of this rapidly growing burden for our future

generation and to mobilize the necessary funding to support research in this area of enormous

societal importance.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

7

EXECUTIVE BOARD

BART DE STROOPER, M.D., PH.D.

Contact address:

Center of Human Genetics

O&N I Herestraat 49 - bus 00602

B-3000 Leuven

Tel: +32 16 34 62 27

Fax: +32 16 34 71 81

E-mail: [email protected]

Web: http://med.kuleuven.be/cme-mg/lncb/index_en.html

EDUCATION AND PROFESSIONAL TRAINING

1985 Doctor in Medicine (M.D.), Faculty of Medicine, K.U.Leuven

1988 Master of Biomedical Sciences, Faculty of Medicine, K.U.Leuven

1989 Ph.D., Center for Human Genetics, K.U.Leuven

1994-1995 Visiting Researcher, European Molecular Biology Laboratory, Heidelberg, Germany

1998-present Group leader, VIB

2002-present Full Professor in Molecular Medicine (Gewoon Hoogleraar), K.U.Leuven

2005-2010 Chairman of the Department of Human Genetics, K.U.Leuven

2007-present Scientific director of the Department of Molecular and Developmental Genetics, VIB

RESEARCH TOPICS

Neuronal cell biology

Gene transfer

Alzheimers and Parkinsons disease

Regulated intramembrane proteolysis

APP, presenilin, -secretase, PARL, pink-1, LRRK2

RESEARCH AREAS

The work in my laboratory is focused on the understanding of the fundamental mechanisms that

underlie neurodegenerative disorders. We work mainly on Alzheimers and Parkinsons Disease and

we start our functional studies with genes identified by human genetics research. We ask what the

biological role is of the protein under investigation, and to what extent disturbance of the normal

function can explain disease relevant phenotypes.

The work on Alzheimers Disease is centered on the Secretases, the proteases which are

involved in the generation of the A-amyloid peptide that precipitates in the amyloid plaques in the

brain of patients. We have been the first group to link presenilins unequivocally with -Secretase

http://med.kuleuven.be/cme-mg/lncb/index_en.html

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

8

activity (De Strooper et al., Nature, 1998) and have since then worked on intramembrane proteolysis

and the role of the different -Secretases. This work has been extremely productive and generated a

series of high impact publications over the years (Thathiah et al., Science, 2009; Serneels et al.,

Science, 2009, and Wakabayashi et al., Nat.Cell biol, 2009).

With regard to Parkinsons disease we are using Drosophila in collaboration with Prof. P. Verstreken,

next to mammalian cells and mouse models. We follow three research lines:

The role of PARL and mitochondrial dysfunction in Parkinson Disease. This work is based on

our Cell paper (Cipolat et al., 2006) demonstrating the essential role of PARL in the control of

cytochrome c release. There are two reports that PARL is involved in the proteolysis of Pink1

which further corroborates the importance of this research line.

The kinome of Pink1. Following up on our paper in EMBO Molecular Med (Vanessa Morais et

al., 2009) we focus on complex I biology to understand how Pink1 affects mitochondrial

function.

The role of LRRK2 in neuronal vesicle transport and release. This work is also done in

collaboration with an industrial partner.

MAJOR SCIENTIFIC AWARDS

Potamkin Prize for Research in Picks, Alzheimers and related Diseases (USA), 2002

Pioneer Award from the American Alzheimer Association (USA), 2002

Alois Alzheimer Award (Germany), 2003

Elected EMBO member, 2004

Joseph Maisin Price for fundamental biomedical sciences (Flanders), 2005

Methusalem grant of the Flemisch Government (Flanders), 2007

MetLife Foundation Award for Medical Research (USA), 2008

UCB Award, 2011

SELECTED PUBLICATIONS

1. Hbert S.S., Papadopoulou A.S., Smith P., Galas M.C., Planel E., Silahtaroglu A.N., Sergeant N.,

Bue L. and De Strooper B. (2010) Genetic ablation of Dicer in adult forebrain neurons results

in abnormal tau hyperphosphorylation and neurodegeneration. Human Molecular Genetics

19(20): 395969.

2. Kuperstein I., Broersen K., Benilova I., Rozenski J., Jonckheere W., Debulpaep M.,

Vandersteen A., SegersNolten I., Van Der Werf K., Subramaniam V., Braeken D., Callewaert

G., Bartic C., D'Hooge R., Martins I.C., Rousseau F., Schymkowitz J., De Strooper B. (2010)

Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the A42

to A40 ratio. EMBO Journal 29: 3408-3420.

3. Morais V.A., Verstreken P., Roethig A., Smet J., Snellinx A., Vanbrabant M., Haddad D., Frezza

C., Mandemakers W., VogtWeisenhorn D., Van Coster R., Wurst W., Scorrano L. and De

Strooper B. (2009) Parkinson's disease mutations in PINK1 result in decreased Complex I

activity and deficient synaptic function. EMBO Molecular Medicine 1(2): 99111.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

9

4. Thathiah A., Spittaels K., Hoffmann M., Staes M., Cohen A., Horr K., Vanbrabant M., Coun F.,

Baekelandt V., Delacourte A., Fischer D.F., Pollet D., De Strooper B. and Merchiers P. (2009)

The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in

neurons. Science 323(5916): 946-51.

5. Serneels L., Van Biervliet J., Craessaerts K., Dejaegere T., Horr K., Van Houtvin T., Esselmann

H., Paul S., Schfer M.K., Berezovska O., Hyman B.T., Sprangers B., Sciot R., Moons L., Jucker

M., Yang Z., May P.C., Karran E., Wiltfang J., D'Hooge R. and De Strooper B. (2009) gamma-

Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science

324(5927): 639-42.

6. Wakabayashi T., Craessaerts K., Bammens L., Bentahir M., Borgions F., Herdewijn P., Staes A.,

Timmerman E., Vandekerckhove J., Rubinstein E., Boucheix C., Gevaert K. and De Strooper B.

(2009) Analysis of the -Secretase interactome and validation of its association with

tetraspanin-enriched microdomains. Nature Cell Biology 11(11): 1340-6.

7. Martins I., Kuperstein I., Wilkinson H., Vanbrabant M., Jonckheere W., Van Gelder P.,

Kmmerer N., PastorHernandez T., Serrano L., Hartmann D., De Strooper B., Schymkowitz J.

and Rousseau F. (2008) Lipids induce release of neurotoxic oligomers from inert amyloid

fibrils. EMBO Journal 27(1): 22433.

8. Hbert S.S., Horr K., Nicola L., Papadopoulou A.S., Mandemakers W., Silahtaroglu A.N.,

Kauppinen S., Delacourte A. and De Strooper B. (2008) Loss of microRNA cluster miR-29a/b-1

in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.

Proceedings of the National Academy of Sciences (PNAS) USA 105(17): 6415-20.

9. Dejaegere T., Serneels L., Schfer M.K., Van Biervliet J., Horr K., Depboylu C., Alvarez-Fischer

D., Herreman A., Willem M., Haass C., Hglinger G.U., D'Hooge R. and De Strooper B. (2008)

Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating

that can be reversed with antipsychotic treatment. Proceedings of the National Academy of

Sciences (PNAS) USA 105(28): 9775-80.

10. Cipolat S., Rudka T., Hartmann D., Costa V., Serneels L., Craessaerts K., Metzger K., Frezza C.,

Annaert W., DAdamio L., Derks C., Dejaegere T., Pellegrini L., DHooge R., Scorrano L. and De

Strooper B. (2006) Mitochondrial rhomboid PARL regulates cytochrome c release during

apoptosis via OPA1-dependent cristae remodelling. Cell 126(1): 163-75.

11. Serneels L., Dejaegere T., Craessaerts K., Horr K., Jorissen E., Tousseyn T., Hbert S., Coolen

M., Martens G., Zwijsen A., Annaert W., Hartmann D. and De Strooper B. (2005) Differential

contribution of the three Aph1 genes to -secretase activity in vivo. Proceedings of the

National Academy of Sciences (PNAS) USA 102(5): 1719-24.

12. Herreman A., Serneels L., Annaert W., Collen D., Schoonjans L., and De Strooper B. (2000)

Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells.

Nature Cell Biology 2: 461-462.

13. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H.,

Schrijvers V., Wolfe M.S., Ray W.J., Goate A. and Kopan R.A. (1999) Presenilin-1-dependent,

gamma-secretase-like protease mediates release of Notch intracellular domain. Nature

398(6727): 518-22.

14. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura

K. and Van Leuven F. (1998) Deficiency of presenilin 1 inhibits the normal cleavage of

Amyloid Precursor Protein. Nature 391: 387-390.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

10

WIM ROBBERECHT, M.D., PH.D.

Contact address:

Division Experimental Neurology

UZ Herestraat 49 - bus 07003

B-3000 Leuven

Tel: + 32 16 34 42 80

Fax: + 32 16 34 42 85

E-mail: [email protected]

EDUCATION AND PROFESSIONAL TRAINING

1984 Medical Degree (Degree of 'Doctor in de genees-, heel- en verloskunde')

1984-1992 Residency and fellowship Neurology (University Hospital Leuven, Belgium; University

of Virginia Medical Center, Charlottesville, Virginia USA and Massachusetts General

Hospital, Boston, US)

1990 Ph.D. (Degree of 'Geaggregeerde van het Hoger Onderwijs', University of Leuven,

Medical School).

1993 Full Appointment as member of the Senior Staff of Department of Neurology,

University Hospital Leuven, University of Leuven, Leuven, Belgium (Adjunct-

Kliniekhoofd)

1994-2004 Clinical Investigator Fund for Scientific Research, Flanders

1997 Professor (Hoogleraar), University of Leuven, Medical School, Leuven

1998-present Director of the Neuromuscular Reference Center, University Hospital Leuven

2001-present Full Professor (Gewoon Hoogleraar), University of Leuven, Medical School, Leuven

2001-present Chairman of the Department of Neurology, University Hospital Leuven, University of

Leuven, Medical School.

2001-2010 Chairman of the Department of Neurosciences, University of Leuven, Medical School,

Leuven

2001-present Chairman of the Section Experimental Neurology, University of Leuven, Medical

School, Leuven

2005 Member of the Board of Administration of the University Hospital Leuven, Leuven

2007 Group leader, Vesalius Research Center, Flanders Institute of Biotechnology

2008 Member of the Board of Administration of the National MS Center, Melsbroek.

2008-present Chairman of the Scientific Advisory Board of the Thierry Latran Foundation for ALS

research

2010-present Chairman of the Program Committee of the Motor Neuron Disease Association,

United Kingdom

RESEARCH TOPICS

Motor neuron degeneration (Amyotrophic Lateral Sclerosis)

mailto:[email protected]

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

11

Neurology/Neuromuscular Diseases

MAJOR SCIENTIFIC AWARDS AND HONORS

Sheila Essey award for ALS research, American Academy of Neurology, 2008

Pfizer visiting Professor Columbia University, New York (USA) 2009

Chair of the Foundation Franqui, University of Hasselt (Belgium) 2010

Brain visiting lectureship, Kings College, London (UK) 2010

Edwards Distinguished ALS Lecture, Houston, Texas (USA) 2010

SELECTED PUBLICATIONS

1. Shatunov A., Mok K., Newhouse S., Weale M.E., Smith B., Vance C., Johnson L., Veldink J.H.,

van Es M.A., van den Berg L.H., Robberecht W., Van Damme P., Hardiman O., Farmer A.E.,

Lewis C.M., Butler A.W., Abel O., Andersen P.M., Fogh I., Silani V., Chi A., Traynor B.J., Melki

J., Meininger V., Landers J.E., McGuffi n P., Glass J.D., Pall H., Leigh P.N., Hardy J., Brown Jr

R.H., Powell J.F., Orrell R.W., Morrison K.E., Shaw P.J., Shaw C.E. and Al-Chalabi A. (2010)

Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other

countries: a genome-wide association study. Lancet Neurology 10: 986-94.

2. Blauw H.M., Al-Chalabi A., Andersen P.M., van Vught P.W.J., Diekstra F.P., van Es M.A., Saris

C.G.J., Groen E.J.N., van Rheenen W., Koppers M., vant Slot R., Strengman E., Estrada K.,

Rivadeneira F., Hofman A., Uitterlinden A.G., Kiemeney L.A., Vermeulen S.H.M., Birve A.,

Waibel S., Meyer T., Cronin S., McLaughlin R.L., Hardiman O., Sapp P.C., Tobin M.D., Wain

L.V., Tomik B., Slowik A., Lemmens R., Rujescu D., Schulte C., Gasser T., Brown Jr R.H.,

Landers J.E., Robberecht W., Ludolph A.C., Ophoff R.A., Veldink J.H. and van den Berg L.H.

(2010) A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Human Molecular

Genetics, doi: 10.1093/hmg/ddq323.

3. Bento-Abreu A., Van Damme P., Van Den Bosch L. and Robberecht W. (2010) The

neurobiology of amyotrophic lateral sclerosis. European Journal of Neuroscience 31: 2247-65.

4. Irobi J., Almeida-Souza L., Asselbergh B., De Winter V., Goethals S., Dierick I., Krishnan J.,

Timmermans J.P., Robberecht W., De Jonghe P., Van Den Bosch L., Janssens S. and

Timmerman V. (2010) Mutant HSPB8 causes motor neuron-specific neurite degeneration.

Human Molecular Genetics 19: 3254-65.

5. Bogaert E., Goris A., Van Damme P., Geelen V., Lemmens R., van Es M.A., van den Berg L.H.,

Kristel Sleegers K., Verpoorten N., Timmerman V., De Jonghe P., Van Broeckhoven C., Traynor

B.J., Landers, J.E., Brown, Jr. R.H., Glass J.D., Al-Chalabi A., Shaw C.E., Birve A., Andersen

P.M., Slowik A., Tomik B., Melki J., Robberecht W. and Van Den Bosch L. (2010)

Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosis.

Neurobiology of Aging, doi:10.1016/j.neurobiolaging.2010.03.007.

6. Taes I., Goris A., Lemmens R., van Es M.A., van den Berg L.H., Chio A., Traynor B.J., Birve A.,

Andersen P., Slowik A., Tomik B., Brown Jr. R.H., Shaw C.E., Al-Chalabi A., Boonen S., Van Den

Bosch L., Dubois B., Van Damme P. and Robberecht W. (2010) Tau levels do not influence

human ALS or motor neuron degeneration in the SOD1G93A mouse. Neurology 74(21): 1687-

93.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

12

7. Lemmens R., Moore M.J., Al-Chalabi A., Brown Jr. R.H. and Robberecht W. (2010) RNA

metabolism and the pathogenesis of motor neuron diseases. Trends in Neurosciences 33(5):

249-58.

8. Wang J.,Van Damme P.,Cruchaga C., Gitcho M.A., Manuel Vidal J., Seijo-Martnez M., Wang

L., Wu J.Y., Robberecht W. and Goate A. (2010) Pathogenic cysteine mutations affect

progranulin function and production of mature granulins. Journal of Neurochemistry 112(5):

1305-15.

9. van Es M.A., Veldink J.H., Saris C.G.J., Blauw H.M., van Vught P.W.J., Birve A., Lemmens R.,

Schelhaas H.J., Groen E.J.N., Huisman M.H.B., van der Kooi A.J., de Visser M., Dahlberg C.,

Estrada K., Rivadeneira F., Hofman A., Zwarts M.J., van Doormaal P.T.C., Rujescu D.,

Strengman E., Giegling I., Muglia P., Tomik B., Slowik A., Uitterlinden A.G., Hendrich C.,

Waibel S., Meyer T., Ludolph A.C., Glass J.D., Purcell S., Cichon S., Nthen M.N., Wichmann

H.E., Schreiber S., Vermeulen S.H.H.M., Kiemeney L.A., Wokke J.H.J., Cronin S., McLaughlin

R.L., Hardiman O., Fumoto K., Pasterkamp R.J., Meininger V., Melki J., Leigh P.N., Shaw C.E.,

Landers J.E., Al-Chalabi A., Brown Jr. R.H., Robberecht W., Andersen P.M., Ophoff R.A. and

van den Berg L.H. (2009) Genome-wide association study identifies 19p13.3 (UNC13A) and

9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nature Genetics 41:

1083-1087.

10. Van Damme P. and Robberecht W. (2009) Recent advances in motor neuron disease. Current

Opinion in Neurology 22: 486-492.

11. Gijselinck I., Sleegers K., Engelborghs S., Robberecht W., Martin J.J., Vandenberghe R., Sciot

R., Dermaut B., Goossens D., van der Zee J., De Pooter T., Del-Favero J., Santens P., De Jonghe

P., De Deyn P.P., Van Broeckhoven C. and Cruts M. (2009) Neuronal inclusion protein TDP-43

has no primary genetic role in FTD and ALS. Neurobiology of Aging 30(8): 1329-31.

12. Brugman F., Veldink J.H., Franssen H., de Visser M., de Jong J.M., Faber C.G., Kremer B.H.,

Schelhaas H.J., van Doorn P.A., Verschuuren J.J., Bruyn R.P., Kuks J.B., Robberecht W., Wokke

J.H. and van den Berg L.H. (2009) Differentiation of hereditary spastic paraparesis from

primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. Archives of

Neurology 66: 509-14.

13. Bogaert E., Van Damme P., Poesen K., Dhondt J., Hersmus N., Kiraly D., Scheveneels W.,

Robberecht W. and Van Den Bosch L. (2009) VEGF protects motor neurons against

excitotoxicity by upregulation of GluR2. Neurobiology of Aging 31(12): 2185-91.

14. Sleegers K., Brouwers N., Van Damme P., Engelborghs S., Gijselinck I., van der Zee J., Peeters

K., Mattheijssens M., Cruts M., Vandenberghe R., De Deyn P.P., Robberecht W. and Van

Broeckhoven C. (2009) Serum biomarker for progranulin-associated frontotemporal lobar

degeneration. Annals of Neurology 65: 603-609.

15. Simpson C.L., Lemmens R., Miskiewicz K., Broom W.J., Hansen V.K., van Vught P.W., Landers

J.E., Sapp P., Van Den Bosch L., Knight J., Neale B.M., Turner M.R., Veldink J.H., Ophoff R.A.,

Tripathi V.B., Beleza A., Shah M.N., Proitsi P., Van Hoecke A., Carmeliet P., Horvitz H.R., Leigh

P.N., Shaw C.E., van den Berg L.H., Sham P.C., Powell J.F., Verstreken P., Brown Jr. R.H.,

Robberecht W., and Al-Chalabi A. (2009) Variants of the elongator protein 3 (ELP3) gene are

associated with motor neuron degeneration. Human Molecular Genetics 18(3): 472-81.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

13

STEERING COMMITTEE MEMBERS

VEERLE BAEKELANDT, PH.D.

Contact address:

Laboratory for Neurobiology and Gene Therapy

Division of Molecular Medicine

K.U.Leuven Faculty of Medicine

Kapucijnenvoer 33 B7001 (VCTB+5)

B-3000 Leuven

Tel: +32 16 33 63 32 or +32 16 33 21 56

Fax: +32 16 33 63 36

E-mail: [email protected]

Website: www.kuleuven.be/molmed

EDUCATION AND PROFESSIONAL TRAINING

1983-1987 Licentiate in Romance languages, K.U.Leuven

1987-1991 Licentiate in biology, group zoology, K.U.Leuven

1995 Ph.D. degree in biology, K.U.Leuven

RESEARCH TOPICS

Parkinsons disease

Adult neurogenesis

Viral vector technology

RESEARCH AREAS

Parkinsons disease (PD) is the second most common neurodegenerative disorder. Over the last 10

years, PD research has been fueled by the identification of genes that are linked to rare familial forms

of the disease. Understanding the function of these genes will undoubtedly provide crucial insights

into the pathogenesis of the more common sporadic forms of PD. Our research focuses on these

familial PD-linked proteins since they provide valuable clues to unravel the pathogenic pathways

involved. We are using viral vector technology and molecular imaging as core technologies to

develop and characterize new cellular and rodent models. Basic insight in the pathogenesis of PD will

help to design and explore new rational, therapeutic strategies based on small molecules, neuronal

stem cells, and/or gene therapy.

Our specific research interests include: the role of -synuclein protein aggregation, the

function of PINK1 and parkin in mitochondrial metabolism, LRRK2 and signal transduction pathways

in PD, and therapeutic modulation of endogenous neural stem cells.

mailto:[email protected]://www.kuleuven.be/molmed

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

14

MAJOR SCIENTIFIC AWARDS

Frank Boas Scholarship (Fulbright Fellowship) for graduate study at Harvard University, 1992-

1993

Triennial scientific prize of the Alumni of Botany and Zoology of Leuven (Belgium) 1997

Biennial prize of the Belgian Society for Stereotactic and Functional Neurosurgery (Belgium)

2002

Biennial Ren De Cooman prize for research related to Aging, 2006

Prize Viscountess Valine de Spoelberch of the Medical Foundation Queen Elisabeth, 2008

SELECTED PUBLICATIONS

1. Carlon M., Toelen J., Van der Perren A., Vandenberghe L.H., Reumers V., Sbragia L., Gijsbers

R., Baekelandt V., Himmelreich U., Wilson J.M., Deprest J. and Debyser Z. Efficient gene

transfer into the mouse lung by fetal intratracheal injection of AAV2/6.2. Molecular Therapy,

in press.

2. Danils V., Vancraenenbroeck R., Law B.M.H., Greggio E., Lobbestael E., Gao F., De Maeyer

M., Cookson M.R., Harvey K., Baekelandt V., Taymans J.-M. Insight into the mode of action of

the LRRK2 Y1699C pathogenic mutant. Journal of Neurochemistry, in press.

3. Fiesel F.C., Voigt A., Weber S.S., Van den Haute C., Waldenmaier A., Grner K., Walter M.,

Anderson M.L., Kern J.V., Rasse T.M., Schmidt T., Springer W, Kirchner R., Bonin M.,

Neumann M., Baekelandt V., Alunni-Fabbroni M., Schulz J.B. and Kahle P.J. (2010)

Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone

deacetylase 6. EMBO Journal 29(1): 209-21.

4. Slaets H., Hendriks J.J.A., Van den Haute C., Coun F., Baekelandt V., Stinissen P. and Hellings

N. (2010) CNS-targeted LIF Expression Improves Therapeutic Efficacy and Limits

Autoimmune-mediated Demyelination in a Model of Multiple Sclerosis. Molecular Therapy

18(4): 684-91.

5. Gerard M., Deleersnijder A., Danils V., Schreurs S., Munck S., Reumers V., Pottel H.,

Engelborghs Y., Van den Haute C., Taymans J.-M., Debyser Z. and Baekelandt V. (2010)

Inhibition of FK506 Binding Proteins reduces alpha-synuclein aggregation and Parkinsons

disease-like pathology. Journal of Neurosciences 30: 2454-2463.

6. Thathiah A., Spittaels K., Hoffmann M., Staes M., Cohen A., Horr K., Vanbrabant M., Coun F.,

Baekelandt V., Delacourte A., Fischer D.F., Pollet D., De Strooper B., and Merchiers P. (2009)

The orphan G protein-coupled receptor 3 is a novel modulator of amyloid-beta peptide

generation in neurons. Science 323(5916): 946-51.

7. Waak J., Springer W., Weber S.S., Waldenmaier A., Grner K., Alunni-Fabbroni M., Vogt-

Weisenhorn D., Pham T.-T., Schtz M., Autenrieth I.B., Reumers V., Baekelandt V., Wurst W.,

and Kahle P.J. (2009) Regulation of Astrocyte Inflammatory Responses by the Parkinsons

Disease-Associated Gene DJ-1. FASEB Journal 23(8): 2478-89.

8. Ibrahimi A., Vande Velde G., Thiry I.,, Reumers V., Vandeputte C., Deroose C., Toelen J.,

Baekelandt V., Debyser Z., Gijsbers R. (2009) Efficient co-expression of multiple imaging

reporters in rodent brain using polycistronic lentivectors. Human Gene Therapy, 20(8): 845-

860.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

15

9. Parisiadou L., Xie C., Lin X., Gu X., Long C.-X., Baekelandt V., Lobbestael E., Taymans J.-M., Sun

L., and Cai H. (2009) Phosphorylation of ERM Proteins by LRRK2 Promotes the

Rearrangement of Actin Cytoskeleton in Neuronal Morphogenesis. Journal of Neurosciences

29(44): 13971-80.

10. Greggio E., Zambrano I., Kaganovich A., Beilina A., Taymans J.-M., Danils V., Lewis P., Jain S.,

Ding J., Syed A., Thomas K.J., Baekelandt V. and Cookson M.R. (2008) The Parkinsons disease

associated Leucine Rich Repeat Kinase 2 (LRRK2) is a dimer that undergoes intra-molecular

autophosphorylation. Journal of Biological Chemistry 283(24): 16906-14.

11. Reumers, V., Deroose C.M., Krylyshkina O., Nuyts J., Geraerts M., Mortelmans L., Gijsbers R.,

Van den Haute C., Debyser Z. and Baekelandt V. (2008) Non-invasive and quantitative

monitoring of adult neuronal stem cell migration in mouse brain using bioluminescence

imaging. Stem Cells 26(9): 2382-9.

12. Lauwers E., Bequ D., Van Laere K., Nuyts J., Bormans G., Mortelmans L., Vercammen L.,

Bockstael O., Nuttin B., Debyser Z. and Baekelandt V. (2007) Non-invasive imaging of

neuropathology in a rat model of alpha-synuclein overexpression. Neurobiology of Aging 28:

248-257.

13. Geraerts M., Krylychkina O., Debyser Z. and Baekelandt V. (2007) Therapeutic strategies for

Parkinsons disease based on the modulation of adult neurogenesis. Stem Cells 25: 263-270.

14. Taymans J.-M., Vandenberghe L., Van den Haute C., Thiry I., Deroose C., Mortelmans L.,

Wilson J.M., Debyser Z., and Baekelandt V. (2007) Comparative Analysis of Adeno-Associated

Viral Vector Serotypes 1, 2, 5, 7, and 8 in Mouse Brain. Human Gene Therapy 18: 195-206.

15. Grard M., Debyser Z., Desender L., Kahle P.J., Baert J., Baekelandt V. and Engelborghs Y.

(2006) The aggregation of alpha-synuclein is stimulated by FK506 Binding Proteins as shown

by Fluorescence Correlation Spectroscopy. FASEB Journal 20(3): 524-526.

16. Geraerts M., Eggermont K., Hernandez-Acosta P., Garcia-Verdugo J.-M., Baekelandt V. and

Debyser Z. (2006) Lentiviral vectors mediate efficient and stable gene transfer in adult neural

stem cells in vivo. Human Gene Therapy 17(6): 635-50.

17. Taymans J.-M., Van den Haute C. and Baekelandt V. (2006) Distribution of PINK1 and LRRK2

in rat and mouse brain. Journal of Neurochemistry 98: 951-961.

18. Deroose C.M., Reumers V., Gijsbers R., Bormans G., Debyser Z., Mortelmans L. and

Baekelandt V. (2006) Noninvasive monitoring of long-term lentiviral vector-mediated gene

expression in rodent brain with bioluminescence imaging. Molecular Therapy 14: 423-431.

19. Vercammen L., Van der Perren A., Vaudano E., Gijsbers R., Debyser Z., Van den Haute C. and

Baekelandt V. (2006) Parkin protects against neurotoxicity in the 6-hydroxydopamine rat

model for Parkinsons disease. Molecular Therapy 14: 716-723.

20. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B. and Baekelandt V. (2003)

Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-

mediated overexpression of -synuclein. Brain Pathology 13: 364-372.

21. Baekelandt V., Eggermont K., Michiels M., Nuttin B. and Debyser Z. (2003) Optimized

lentiviral vector production and purification procedure prevents immune response after

transduction of mouse brain. Gene Therapy 10: 1933-1940.

22. Van den Haute C., Eggermont K., Nuttin B., Debyser Z. and Baekelandt V. (2003) Lentiviral

vector-mediated delivery of short hairpin RNA results in persistent knock-down of gene

expression in mouse brain. Human Gene Therapy 14: 1799-1807.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

16

PETER CARMELIET, M.D., PH.D.

Contact address:

Vesalius Research Centrum

O&N I Herestraat 49 - bus 00912

B-3000 Leuven

Tel: + 32 16 34 57 74

Fax: + 32 16 34 59 90

E-mail: [email protected]

EDUCATION AND PROFESSIONAL TRAINING

1985-1989 Aspirant National Fund for Scientific Research of Belgium (NFWO)

1990-1994 Research Associate National Fund for Scientific Research of Belgium (Aangesteld

Navorser, NFWO)

1993-1995 Lecturer in "Master & Ph.D. Program in Medical and Pharmaceutical Research", Free

University of Brussels

1993-1996 Member of the Bureau of the Department of Molecular and Cardiovascular Biology,

Faculty of Medicine, University of Leuven

1994-1998 Associate Professor (Hoofddocent), Faculty of Medicine, University of Leuven,

Belgium

1994-1996 Adjunct Staff, Cleveland Clinic Foundation, USA

1995-1997 Visiting Professor, Free University of Brussels

1996-2008 Adjunct-Director, Center Transgene Technology & Gene Therapy, Flanders

Interuniversity Institute for Biotechnology, University of Leuven, Belgium.

1996-present Ph.D. thesis committee, Faculty of Medicine, University of Leuven, Belgium

1996-1997 Student-Researcher committee, Faculty of Medicine, University of Leuven, Belgium

1998-2000 Professor (Hoogleraar), Faculty of Medicine, University of Leuven, Belgium

1999-present Professor, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands

2000-present Full Professor (Gewoon Hoogleraar), Faculty of Medicine, University of Leuven,

Belgium

2004-present Visiting Professor, Darthmouth University, NH, USA

2008-present Director, Vesalius Research Center, Vlaams Instituut voor Biotechnologie, VIB

RESEARCH TOPICS

Using genetic and gene-manipulation technologies in mice, zebrafish, Xenopus and humans

angiogenesis and lymphangiogenesis in health and disease

neurodegeneration; in particular the role of VEGF in motor neuron degeneration

(ALS)

neurovascular link and oxygen sensing

mailto:[email protected]

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

17

MAJOR SCIENTIFIC AWARDS

Paulo Gontijo Prize, Instituto Paulo Gontijo, Sao Paulo (Brazil) 2009

Francqui Leerstoel, Universit Catholique de Louvain, Brussels (Belgium) 2008

Francqui Leerstoel, University of Brussels (Belgium) 2007

Francqui Leerstoel, University of Liege (Belgium) 2006

Lucian Award for research in Circulatory Disease, McGill University, 2007

Presidential Special Lecture, Society of Neuroscience Annual meeting, Atlanta (USA) 2006

Feodor Lynen Lecture, Nature Biotechnology Winter Symposium, Miami (USA) 2006

Interbrew-Baillet Latour Prize (Belgium) 2005 (jointly with Dsir Collen)

Liliane Bettencourt Life Sciences Award, 2002

Francqui Prize, Belgian Academy Medicine (Belgium) 2002

SELECTED PUBLICATIONS

1. Mazzone M., Dettori D, Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y., Lanahan

A.A., Pollard P., Ruiz de Almodovar C., De Smet F., Vinckier S., Aragones J., Luttun A., Wyns S.,

Jordan B., Pisacane A., Gallez B., Lampugnani M.G., Dejana E., Simons M., Ratcliffe P.,

Maxwell P. and Carmeliet P. (2009) Heterozygous deficiency of PHD2 restores tumor

oxygenation and inhibits metastasis via endothelial normalization. Cell 136(5): 839-51.

2. Aragones J., Schneider M., Van Geyte K., Fraisl P., Dresselaers T., Mazzone M., Dirkx R.,

Zacchigna S., Lemieux H., Jeoung N.H., Lambrechts D., Bishop T., Lafuste P., Diez-Juan A.,

Harten S. K., Van Noten P., De Bock K., Willam C., Tjwa M., Grosfeld A., Navet R., Moons L.,

Vandendriessche T., Deroose C., Wijeyekoon B., Nuyts J., Jordan B., Silasi-Mansat R., Lupu F.,

Dewerchin M., Pugh C., Salmon P., Mortelmans L., Gallez B., Gorus F., Buyse J., Sluse F.,

Harris R.A., Gnaiger E., Hespel P., Van Hecke P., Schuit F., Van Veldhoven P., Ratcliffe P., Baes

M., Maxwell P. and Carmeliet P. (2008) Deficiency or inhibition of oxygen sensor Phd1

induces hypoxia tolerance by reprogramming basal metabolism. Nature Genetics 40(2): 170-

80.

3. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E.,

Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van

Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D. and Carmeliet P. (2007) Anti-

PlGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels.

Cell 131(3): 463-75.

4. Ny A., Koch M., Schneider M., Neven E., Tong R.T., Maity S., Fischer C., Plaisance S.,

Lambrechts D., Heligon C., Terclavers S., Ciesiolka M., Kalin R., Man W.Y., Senn I., Wyns S.,

Lupu F., Brandli A., Vleminckx K., Collen D., Dewerchin M., Conway E.M., Moons L., Jain R.K.

and Carmeliet P. (2005) A genetic Xenopus laevis tadpole model to study lymphangiogenesis.

Nature Medicine 11: 998-1004.

5. Storkebaum E., Lambrechts D., Dewerchin M., Moreno-Murciano M.P., Appelmans S., Oh H.,

Van Damme P., Rutten B., Man W.Y., De Mol M., Wyns S., Manka D., Vermeulen K., Van Den

Bosch L., Mertens N., Schmitz C., Robberecht W., Conway E.M., Collen D., Moons L. and

Carmeliet P. (2005) Treatment of motoneuron degeneration by intracerebro-ventricular

delivery of VEGF in a rat model of ALS. Nature Neuroscience 8: 85-92.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

18

RUDI DHOOGE, PH.D.

Contact address:

Laboratory of Biological Psychology

Katholieke Universiteit Leuven

Tiensestraat 102

B-3000 Leuven

Tel: + 32 16 32 61 42

E-mail: [email protected]

EDUCATION AND PROFESSIONAL TRAINING

1988 Masters Degree in Biotechnology, Antwerp University [Licentiaat in de Dierkunde

Biotechnologie, UIA]

1990 Masters Degree in Experimental Psychology, Brussels University [Licentiaat in de

Psychologie, Optie Experimentele Psychologie, VUB]

1994 Ph.D., Doctor in Biomedical Sciences, Antwerp University

1996-2003 Assistant professor & senior researcher at Born-Bunge Foundation

2002 Ph.D., Doctor in Psychology, Brussels University (VUB)

2003-present Head of Laboratory of Biological Psychology, Dept. Psychology, K.U.Leuven

2003-2007 Professor, Dept. Psychology, K.U.Leuven

2007-present Full professor, Dept. Psychology, K.U.Leuven

RESEARCH TOPICS

Mechanisms of neural and behavioural plasticity; learning and memory

Biopsychological mechanisms of brain and behavioural disorders

Preclinical studies on pathophysiology & treatment of neurocognitive disorders (including

metabolic brain disease, neurodegenerative and neurodevelopmental disorders, etc.)

Behavioural assessment and brain activity recording techniques in rodent models

MAJOR SCIENTIFIC AWARDS

Postdoctoral fellowship funded by Research Fund FWO-Vlaanderen at UA Association Health

Science Dept., University of Antwerp (Belgium) 1997-2003

Ph.D. studentship funded by Flemish research fund IWONL/IWT atUA Association Health

Science Dept., University of Antwerp (Belgium) 1992-1995

mailto:[email protected]

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

19

SELECTED PUBLICATIONS

1. Vervoort R., Ceulemans H., Van Aerschot L., D'Hooge R. and David G. (2010) Genetic

modification of the inner ear lateral semicircular canal phenotype of the Bmp4 haplo-

insufficient mouse. Biochemical and Biophysical Research Communications 394: 780-785.

2. Glyvuk N., Tsytsyura Y., Geumann C., D'Hooge R., Hve J., Kratzke M., Baltes J., Bning D.,

Klingauf J. and Schu P. (2010) AP-1/1B-adaptin mediates endosomal synaptic vesicle

recycling, learning and memory. EMBO Journal 29: 1318-1330.

3. Woolley D.G., Vermaercke B., Op de Beeck H., Wagemans J., Gantois I., D'Hooge R., Swinnen

S.P. and Wenderoth N. (2010) Sex differences in human virtual water maze performance:

Novel measures reveal the relative contribution of directional responding and spatial

knowledge. Behavioural Brain Research 208: 408-414.

4. Coremans V., Ahmed T., Balschun D., DHooge R., De Vriese A., Cremer J., Antonucci F.,

Moons M., Baekelandt V., Reumers V., Cremer H., Eisch A., Lagace D., Janssens T., Bozzi Y.,

Caleo M. and Conway E. (2010) Impaired neurogenesis, learning and memory and low seizure

threshold associated with loss of neural precursor cell survivin. BMC Neuroscience 11: 2.

5. Balschun D., Moechars D., Callaerts-Vegh Z., Vermaercke B., Van Acker N., Andries L. and

DHooge R. (2010) Vesicular glutamate transporter VGLUT1 has a role in hippocampal long-

term potentiation and spatial reversal learning. Cerebral Cortex 20: 684-693.

6. Leo S., D'Hooge R. andMeert T. (2010) Exploring the role of nociceptor-specific sodium

channels in pain transmission using Na(v)1.8 and Na(v)1.9 knockout mice. Behavioural Brain

Research 208: 149-157.

7. Kalus I., Salmen B., Viebahn C., von Figura K., Schmitz D., D'Hooge R. and Dierks T. (2009)

Differential involvement of the extracellular 6-O-endosulfatases Sulf1 and Sulf2 in brain

development, and neuronal and behavioral plasticity. Journal of Cellular and Molecular

Medicine 13: 4505-4521.

8. Leo S., Moechars D., Callaerts-Vegh Z., DHooge R. and Meert T. (2009) Impairment of

VGLUT2 but not VGLUT1 signaling reduces neuropathy-induced hypersensitivity. European

Journal of Pain 13: 1008-1017.

9. Van Calsteren K., Hartmann D., Van Aerschot L., Verbesselt R., Van Bree R., DHooge R. and

Amant F. (2009) Vinblastine and doxorubicin administration to pregnant mice affects brain

development and behaviour in the offspring. Neurotoxicology 30: 647-657.

10. Kerkhof I., Goesaert E., Dirikx T., Vansteenwegen D., Baeyens F., DHooge R. and Hermans D.

(2009) Assessing valence indirectly and online. Cognition & Emotion 23: 1615-1629.

11. Leroy T., Stroobants S., Aerts J.-M., DHooge R. and Berckmans D. (2009) Automatic analysis

of altered gait in arylsulfatase A-deficient mice in the open field. Behavior Research Methods

41: 787-794.

12. Matzner U., Lllmann-Rauch R., Stroobants S., Andersson C., Weigelt C., Eistrup C., Fogh J.,

DHooge R. and Gieselmann V. (2009) Enzyme replacement improves ataxic gait and central

nervous system histopathology in a mouse model of metachromatic leukodystrophy.

Molecular Therapy 17: 600-606.

13. Bollen B., Bouslama M., Matrot B., Rotrou Y., Vardon G., Lofaso F., Van den Bergh O.,

DHooge R. and Gallego J. (2009) Cold stimulates the behavioral response to hypoxia in

newborn mice. American Journal of Physiology (Regulatory, Integrative and Comparative

Physiology) 296: R1503-1511.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

20

14. Serneels L., Van Biervliet J., Craessaerts K., Dejaegere T., Horr K., Van Houtvin T., Esselmann

H., Paul S., Schfer M.K., Berezovska O., Hyman B.T., Sprangers B., Sciot R., Moons L., Jucker

M., Yang Z., May P.C., Karran E., Wiltfang J., DHooge R. and De Strooper B. (2009) -

Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimers Disease. Science 324:

639-642.

15. Goddyn H., Callaerts-Vegh Z., Stroobants S., Dirikx T., Vansteenwegen D., Hermans D., van

der Putten H. and D'Hooge R. (2008) Deficits in acquisition and extinction of conditioned

responses in mGluR7 knockout mice. Neurobiology of Learning & Memory 90: 103-111.

16. Callaerts-Vegh Z., Beckers T., Ball S.M., Baeyens F., Callaerts P.F., Cryan J.F., Molnar E. and

DHooge R. (2006) Concomitant deficits in working memory and fear extinction are

functionally dissociated from reduced anxiety in mGluR7-deficient mice. Journal of

Neurosciences 26: 6573-6582.

17. DHooge R., Lllmann-Rauch R., Beckers T., Balschun D., Schwake M., Reiss K. and Saftig P.

(2005) Neurocognitive and psychotiform behavioral alterations and enhanced hippocampal

long-term potentiation in transgenic mice displaying neuropathological features of human

alpha-mannosidosis. Journal of Neurosciences 25: 6539-6549.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

21

PETER JANSSEN, M.D., PH.D.

Contact address:

Division Neurophysiology

O&N II Herestraat 49, bus 1021

B-3000 Leuven

Tel: +32 16 34 57 45

Fax: +32 16 34 59 93

E-mail: [email protected]

Website: www.neuroserv.kuleuven.be

EDUCATION AND PROFESSIONAL TRAINING

1996 Master in Medicine, K.U.Leuven, Belgium

1996 Master in Psychology, K.U.Leuven, Belgium

2000 PhD in Medical Sciences, K.U.Leuven, Belgium

2001-2003 postdoctoral researcher, University of Washington, Seattle, WA, USA

RESEARCH TOPICS

The representation of objects in the dorsal visual stream

The neural basis of perceptual judgments on 3D shape from disparity

Functional interactions between premotor and parietal cortex during visually-guided

grasping

The premotor cortex in monkeys and humans

Spatial attention and the planning of eye movements

The relation between haemodynamic responses and neural responses studied with fMRI and

single-cell recordings

Amygdala kindling as a model for temporal lobe epilepsy

RESEARCH AREAS

We live in a three-dimensional (3D) world. In everyday life, we continuously interact with objects in

an effortless way: we scrutinize the world with our eye movements; we recognize, grasp and

manipulate objects skillfully and at a remarkable speed. My research focuses on the neural basis of

3D object vision. The areas involved in the visual analysis of 3D objects for recognition and actions

are located in the parietal, premotor and inferotemporal cortex. To elucidate the underlying neural

mechanisms we employ an integrated approach, in which single-cell recordings, electrical

microstimulation, reversible inactivation and fMRI are combined. In this way we achieve high spatial

and temporal resolution (the responses of single neurons recorded on a timescale of milliseconds), a

general overview of the brain areas activated by 3D stimuli (fMRI) and causal techniques to study the

relation between neural activity and behavior (microstimulation and inactivation) . We use the only

animal model that is relevant to study these high-level cognitive processes: the macaque monkey.

mailto:[email protected]://www.neuroserv.kuleuven.be/

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

22

When possible, studies on human patients provide invaluable information that can be compared with

the data acquired in the monkey.

More recently, we started to investigate the neural basis of temporal lobe epilepsy using an

amygdala kindling model in the macaque monkey. With this model we can carefully study the

process of epileptogenesis in a longitudinal way using PET and MR imaging combined with single-cell

and local field potential recordings.

MAJOR SCIENTIFIC AWARDS

Award of the Research Council of the K.U.Leuven for Biomedical Sciences (Belgium) 2001

Honorary fellowship of the Belgian-American Educational Foundation, 2001

Career Development Award of the Human Frontiers Science Program, 2005

SELECTED PUBLICATIONS

1. Verhoef B.-E., Vogels R. and Janssen, P. (2010) The contribution of inferior temporal and

posterior parietal activity to three-dimensional shape perception. Current Biology 20: 909-

913.

2. Srivastava S., Orban G. A., De Maziere P. and Janssen P. (2009) A distinct representation of three-

dimensional shape in macaque anterior intraparietal area: fast, metric and coarse. Journal of

Neuroscience 29: 10613-10626.

3. Janssen P., Srivastava S., Ombelet S. and Orban G.A. (2008) Coding of shape and position in

macaque lateral intraparietal area. Journal of Neuroscience 28: 6679-6690.

4. Janssen P. and Shadlen M. N. (2005) A representation of the hazard rate of elapsed time in

macaque area LIP. Nature Neuroscience 8: 234-241.

5. Janssen P., Vogels R., Liu Y. and Orban G. A. (2003) At least in inferior temporal cortex the

stereo correspondence problem is solved. Neuron 37: 693-701.

6. Janssen P., Vogels R. and Orban G. A. (2000a) Selectivity for three-dimensional shape that

reveals distinct areas in macaque inferior temporal cortex. Science 288: 2054-2056.

7. Janssen P., Vogels R. and Orban G. A. (2000b) Three-dimensional shape coding in inferior

temporal cortex. Neuron 27: 385-397.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

23

STEFAN SUNAERT, M.D., PH.D.

Contact address:

Dept. of Radiology Medical Imaging Research Center

Herestraat 49

B-3000 Leuven

Tel: +32 16 34 37 71

Fax: +32 16 34 37 65

E-mail: [email protected]

Website: http://mic.uzleuven.be

EDUCATION AND PROFESSIONAL TRAINING

1995 Medicine, Catholic University of Leuven, Belgium

2001 Doctor in the Medical Sciences, Catholic University of Leuven, Belgium

2002 Radiology, Catholic University of Leuven, Belgium

RESEARCH TOPICS

Magnetic resonance imaging

MR imaging

Analysis of neuroanatomic and neurofunctional substrates in autism

Structural and functional imaging in neurodevelopment and neurodegeneration

Functional and diffusion tensor magnetic resonance imaging

RESEARCH AREAS

The main research topic is the study of the functional and structural organization of the normal and

pathological human brain by the combination of functional MRI and diffusion tensor imaging.

The current research topics are structured along three lines:

1/ Investment and research in large imaging infrastructure (MRI at 1.5 and 3T; EEG).

2/ Promotorship of PhD students:

S. Kovacs on the topic The use of fMRI and DTI for the non-invasive characterization and

treatment of non-pulsatile tinnitus

C. Sage on the topic fMRI and DTI of the pathogenesis of amyotrophic lateral sclerosis

J. Verhoeven on the topic Imaging of the neuro-anatomical and neuro-functional subtrates

of autism

S. Deprez on the topic MRI of the cognitive dysfunction in patients with adjuvant

chemotherapy

mailto:[email protected]://mic.uzleuven.be/

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

24

3/ Involvement in other projects, including:

Structural and functional imaging in neurodevelopment and neurodegeneration

Endophenotyping of the autism spectrum disorder: neurocognition and brain imaging.

Cortical mechanisms of attentional shift towards visual objects: combined EEG-FMRI studies.

Dyslexia as an auditory temporal information disorder

Structural plasticity of the adult brain.

Integration of EEG and fMRI

The contribution of cortical areas in higher order sensorimotor control as determined by

fMRI

Impact of new treatment strategies on the long-term morbidity of the neonate-at-risk

Sensory functions in cerebral palsy.

Structure and function of the cerebral cortex in the human and non-human primate

3T MRI for the non-invasive anatomical and functional imaging of large animals

MAJOR SCIENTIFIC AWARDS

Winner of the Horlait-Dapsens Medical Scholarship, 2001

Nomination of Excellence for the Sixth Lucien Appel Prize for Neuroradiology, 2002

Winner of the ECR 2004 Research & Education Fund, 2004

1st prize of the Best Scientific Paper Awards 2006 within the topic "Neuro" during the 18th

European Congress of Radiology (ECR) 2006, Vienna (Austria) 2006

Course Director of the European Society for Magnetic Resonance in Medicine and Biology

(ESMRMB) School of MRI on clinical fMRI, 2007

Winner of the Outstanding Teaching Award of the International Society for Magnetic

Resonance in Medicine (ISMRM), 2008

Section Editor of the journal Neuroradiology, 2008

Member of the Annual Meeting Program Committee (AMPC) of the 17th Scientific Meeting &

Exhibition of the international society of magnetic resonance imaging in medicine (ISMRM),

2009

Member of the Postgraduate Educational Programme (PEP) of the European Congress of

Radiology 2010 (European Society for Radiology), 2010

Chair of the Scientific Program Committee of the European Society for Magnetic Resonance

in Medicine and Biology (ESMRMB) congress in 2012, 2010

SELECTED PUBLICATIONS

1. Sage C. A., Van Hecke W., Peeters R., Sijbers J., Robberecht W., Parizel P., Marchal G.,

Leemans A. and Sunaert S. (2009) Quantitative diffusion tensor imaging in amyotrophic

lateral sclerosis: Revisited. Human Brain Mapping 30(11): 3657-3675.

2. Sage C.A., Peeters R., Grner A., Robberecht W. and Sunaert S. (2007) Quantitative diffusion

tensor imaging in amyotrophic lateral sclerosis. NeuroImage 2: 486-499.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

25

3. Thomas B., Eyssen M., Peeters R., Molenaers G., Van Hecke P., De Cock P. and Sunaert S.

(2005) Quantitative diffusion tensor imaging in cerebral palsy due to periventricular white

matter injury. Brain 11: 2562-2577.

4. Vanduffel W., Fize D., Peuskens H., Denys K., Sunaert S., Todd J.T. and Orban G. (2002)

Extracting 3D from motion: differences in human and monkey intraparietal cortex. Science

5592: 413-5.

5. Sunaert S., Van Hecke P., Marchal G. and Orban G. (1999) Motion-responsive regions of the

human brain. Experimental brain research 4: 355-70.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

26

KOEN VAN LAERE, M.D., PH.D., D.SC.

Contact address:

Division of Nuclear Medicine

E901, Herestraat 49

B-3000 Leuven

Tel: +32 16 34 37 13

Fax: +32 16 34 37 59

E-mail: [email protected]

Website: www.kuleuven.be/nucmed

EDUCATION AND PROFESSIONAL TRAINING

1987 Licence (M.Sc.) physics, Ghent University, Belgium

1992 Ph.D. in radiation physics, Ghent University, Belgium

1997 Medical doctor, Ghent University, Belgium

2001 Ph.D. in Medical Sciences, Ghent University, Belgium

2002 Board Certified Specialist in Nuclear Medicine

2007 Full professor faculty of Medicine

RESEARCH TOPICS

Positron Emission Tomography (PET) imaging in primary and secondary neurodegeneration,

especially focused on protein and neuroreceptor imaging

PET Imaging for CNS drug development

RESEARCH AREAS

1. Development and evaluation of new fluorine-18 labeled tracer agents for study of amyloid and

tau pathology in human brain and for therapy follow-up of disease modifying drugs in

Alzheimers disease, other dementing disorders, amyloid angiopathy and old age depression

(collab Prof. R. Vandenberghe, Prof. M. Vandenbulcke, Prof. V. Thijs).

2. Development and evaluation of tracers for study of endocannabinoid related pathology in the

human brain (Prof. D. Lambert (UCL), Prof. J. van Os (Maastricht), Prof. M. Leweke (MPI Cologne,

Mannheim, Prof. W.Vandenberghe, Prof.M.Vandenbulcke). We have established an intensive

(pre)clinical endocannabinoid imaging research team and the established first successful clinical

imaging of both CB1 receptors (collab. with Merck, USA) and CB2 receptors, which are

investigated in neurodegeneration and neuroinflammation.

3. Validation of animal models for neurodegenerative disorders enabling biomarker development

and stem cell therapy (collab. Prof. V. Baekelandt, Prof. O. Riess (U. Tubingen), Prof. C.Verfaillie):

Objective preclinical molecular neuroimaging data will be used to validate these animal models

and surpass the limitations of the currently used behavioural tests. New imaging strategies for

stem cell therapy are being developed and validated.

http://www.kuleuven.be/nucmed

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

27

4. Development and evaluation of tracer agents for study of dopamine (DA) related pathology in

the human brain [dopamine transporters, D2/D3 receptors, dopamine release; collab. Prof. S.

Claes, Prof. J. van Os (U. Maastricht)], e.g. in movement disorders and psychiatric disorders

(depression, psychosis).

5. Development of an optimized CNS image reconstruction and processing pipeline applicable to

quantitative CNS studies from rodent to man: The research goal is to improve the image quality

and quantification in PET and SPECT using complementary multimodal sources, in particular MRI,

for improved reconstruction, partial volume correction and automated sensitive voxelwise

analysis.

6. Development and clinical application of novel tracers for in vivo quantification in

neurodegenerative diseases (e.g. phosphodiesterase type 10A in movement disorders, histamine

H3 receptor, ).

MAJOR SCIENTIFIC AWARDS

First Prize "Specia" Faculty of Medicine Ghent University, for exceptional study efforts, 1997

Second prize Society of Nuclear Medicine (SNM) "Best Basic Science Investigation of the year

2000", 2001

"Van Vaerenbergh - De Visscher" award, Belgian Society for Nuclear Medicine, 2002

Alavi-Mandell award in Nuclear Medicine, Society for Nuclear Medicine (USA) 2002

Scientific Prize Pfizer for best PhD dissertation in medical sciences 2002, Ghent University

(Belgium) 2002

SELECTED PUBLICATIONS

1. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon A., Salmon E., Bastin C., Triau E.,

Hasselbalch S., Law I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans

G., Bucley C., Owenius R., Thurfjell L., Farrar G. and Brooks D.J. (2010) 18F-flutemetamol

amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals

of Neurology 68(3): 319-329.

2. Van Laere K., Cleerinckx K., Dhont E., de Groot T. and Vandenberghe W. (2010) Combined

striatal binding and cerebral influx analysis of dynamic 11C-Raclopride PET improves early

differentiation between multiple-system atrophy and Parkinsons Disease. Journal of Nuclear

Medicine 51(4): 588-595.

3. Burns D., Van Laere K., Sanabria-Bohrquez S., Hamill T., Bormans G., Wai-Si E., Gibson R.,

Ryan C., Conolly B., Vanko A., Patel S., Krause S., Van Hecken A., Dupont P., De Lepeleire I.,

Rothenberg P., Stoch S., Cote J., Hagmann W., Jewell J., Lin L., Liu P., Goulet M., Gottesdiener

K., Wagner J., de Hoon J., Mortelmans L., Fong T. and Hargreaves R. (2007) [18F]MK-9470, a

positron emission tomography (PET) tracer for in vivo human PET brain imaging of the

Cannabinoid-type 1 receptor. Proceedings of the National Academy of Sciences (PNAS) USA

104(23): 9800-9805.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

28

RIK VANDENBERGHE, M.D., PH.D.

Contact address:

Neurology

University Hospital Leuven

Herestraat 49

B-3000 Leuven

Tel: +32 16 34 42 80

Fax: +32 16 34 42 85

E-mail: [email protected]

Website: http://med.kuleuven.be/lcn/

http://www.uzleuven.be/geheugenkliniek/

EDUCATION AND PROFESSIONAL TRAINING

1991 Degree of Medical Doctor, Faculty of Medicine, K.U.Leuven, Belgium

1993-1997 Research fellow of the National Fund for Scientific Research (N.F.W.O.), Laboratorium

voor Neuro- en Psychofysiologie (director: Professor Dr. G.A. Orban), Faculty of

Medicine, K.U.Leuven, Belgium

1995-1997 Research Fellow, Functional Imaging Laboratory, Wellcome Department of Cognitive

Neurology (director: Professor Dr. R.S.J. Frackowiak), Institute of Neurology, Queen

Square, London, United Kingdom

1997 Ph.D. degree, "The Anatomy of Visual Cognition Measured with Positron Emission

Tomography", advisor Professor Dr. G.A. Orban, Faculty of Medicine, K.U.Leuven,

Belgium

1997-1999 Affiliated Lecturer, Faculty of Medicine, University of Cambridge, Cambridge, United

Kingdom

1999-present Registered as Specialist in Neurology, K.U.Leuven, Belgium

1999-2000 Human Frontiers Long-term Fellowship, Cognitive Neurology and Alzheimer's Disease

Center (director: Professor Dr. M.M. Mesulam), Northwestern University Medical

School, Chicago, IL, U.S.A.

2000-present Associate Professor at the Faculty of Medicine, K.U.Leuven

RESEARCH TOPICS

Functional neuroanatomy of language and spatial attention

Clinical research in cortical neurodegenerative disease (Alzheimer, Frontotemporal

degeneration)

RESEARCH AREAS

Rik Vandenberghe is director of the memory clinic of the University Hospitals Leuven and, since 2005,

head of the newly founded Laboratory for Cognitive Neurology, K.U.Leuven. The memory clinic of the

mailto:[email protected]://med.kuleuven.be/lcn/http://www.uzleuven.be/geheugenkliniek/

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

29

University Hospitals Leuven is part of the European Alzheimer's Disease Consortium (EADC) and

provides early diagnosis, treatment and care for patients with Alzheimer's disease and

frontotemporal degeneration across the disease spectrum with a special interest in early-onset

dementia as well as atypical variants (primary progressive aphasia, posterior cortical atrophy). The

memory clinic also actively contributes to biomarker and clinical drug development (phase 1, 2, and

3), both investigator-driven and through collaboration with industrial partners. The Laboratory for

Cognitive Neurology is part of a K.U.Leuven Centre of Excellence and combines cognitive research in

cognitively intact volunteers with studies in patients with cortical neurodegenerative disease and

focal cortical stroke using different methodologies from behavioral assessment over functional

magnetic resonance imaging to molecular imaging. The two primary aims are to define the

organization of brain circuits for language and spatial attention in the intact brain and the underlying

pathophysiological mechanisms leading to clinical dysfunction (http://med.kuleuven.be/lcn/).

MAJOR SCIENTIFIC AWARDS

Inbev-Baillet Latour Clinical Research Prize, 2007

Queen Elisabeth Medical Foundation UCB scientific award for neuroscience (Belgium) 2008

SELECTED PUBLICATIONS

1. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law

I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans G., Buckley C.,

Owenius R., Thurfjell L., Farrar G. and Brooks D.J. (2010) 18F-flutemetamol amyloid imaging

in Alzheimer's disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology

68: 319-329.

2. Nelissen N., Pazzaglia M., Vandenbulcke M., Sunaert S., Fannes K., Dupont P., Aglioti S.M.,

Vandenberghe R. (2010) Gesture discrimination in primary progressive aphasia: the

intersection between gesture and language processing pathways. Journal of Neurosciences

30: 6334-6341.

3. Nelissen N., Van Laere K., Thurfjell L., Owenius R., Vandenbulcke M., Koole M., Bormans G.,

Brooks D.J. and Vandenberghe R. (2009) Phase I study of the PIB derivative 18F-flutemetamol

in healthy volunteers and patients with probable Alzheimer's disease. Journal of Nuclear

Medicine 50: 1251-1259.

4. Molenberghs P., Peeters R. and Vandenberghe R. (2008) Convergence between lesion-

symptom mapping and fMRI of spatially selective attention in the intact brain. Journal of

Neurosciences 28: 3359-3373.

5. Nelissen N., Vandenbulcke M., Fannes K., Verbruggen A., Peeters R., Dupont P., Van Laere K.,

Bormans G. and Vandenberghe R. (2007) Abeta amyloid deposition in the language system

and how the brain responds. Brain 130: 2055-2069.

6. Molenberghs P., Mesulam M.M., Peeters R. and Vandenberghe R. (2007) Remapping

attentional priorities: Differential contribution of superior parietal lobule and intraparietal

sulcus. Cerebral Cortex 17: 2703-2712.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

30

7. Vandenbulcke M., Peeters R., Fannes K. and Vandenberghe R. (2006) Knowledge of visual

attributes in the right hemisphere. Nature Neuroscience 9: 964-970.

8. Vandenbulcke M., Peeters R., Dupont P., Van Hecke P. and Vandenberghe R. (2007) Word

reading and posterior temporal dysfunction in amnestic mild cognitive impairment. Cerebral

Cortex 17: 542-551.

9. Theuns J., Marjaux E., Vandenbulcke M., Van Laere K., Kumar-Singh S., Bormans G., Van den

Broeck M., Vennekens K., Corsmit E., De Strooper B., Van Broeckhoven C. and Vandenberghe

R. (2006) Alzheimer dementia caused by a novel mutation located in the APP C-terminal

intracytosolic fragment. Human Mutation 27: 888-896.

10. Cruts M., Gijselinck I., van der Zee J., Engelborghs S., Wils H., Pirici D., Rademakers R.,

Vandenberghe R., Dermaut B., Martin J.J., van Duijn C., Peeters K., Sciot R., Santens P., De

Pooter T., Mattheijssens M., Van den Broeck M., Cuijt I., Vennekens K., De Deyn P.P., Kumar-

Singh S., Van Broeckhoven C. (2006) Null mutations in progranulin cause ubiquitin-positive

frontotemporal dementia linked to chromosome 17q21. Nature 442: 920-924.

11. Vandenbulcke M., Peeters R., Van Hecke P. and Vandenberghe R. (2005) Anterior temporal

laterality in primary progressive aphasia shifts to the right. Annals of Neurology 58: 362-370.

12. Vandenberghe R., Geeraerts S., Molenberghs P., Lafosse C., Vandenbulcke M., Peeters K.,

Peeters M., Van Hecke P. and Orban G.A. (2005) Attentional responses to un-attended

stimuli in human parietal cortex, Brain 128: 2843-2857.

13. Vandenberghe R., Vandenbulcke M., Weintraub S., Johnson N., Porke K., Thompson C.K. and

Mesulam M. (2005) Paradoxical features of word finding difficulty in primary progressive

aphasia. Annals of Neurology 57: 204-209.

14. Vandenberghe R., Nobre A.C. and Price C.J. (2002) The response of left temporal cortex to

sentences. The Journal of Cognitive Neuroscience 14: 550-560.

15. Vandenberghe R., Gitelman D.R., Parrish T.B. and Mesulam M.M. (2001) Functional

specificity of superior parietal mediation of spatial shifting. NeuroImage 14: 661-673.

16. Mummery C.J., Patterson K., Wise R., Vandenberghe R., Price C.J. and Hodges J. (1999)

Disrupted temporal lobe connections in semantic dementia. Brain 122: 61-73.

17. Vandenberghe R., Duncan J., Dupont P., Ward R., Poline J.B., Bormans G., Michiels J.,

Mortelmans L. and Orban G.A. (1997) Attention to one or two features in left or right visual

field: a PET study. The Journal of Neuroscience 17: 3739-3750.

18. Vandenberghe R., Price C., Wise R., Josephs O. and Frackowiak R.S.J. (1996) Functional

anatomy of a common semantic system for words and pictures. Nature 383: 254-256.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

31

PATRIK VERSTREKEN, PH.D.

Contact address:

Laboratory of Neuronal Communication

O&N3, Herestraat 49 bus 602

B-3000 Leuven

Tel: +32 16 33 00 18

Fax: +32 16 34 71 90

E-mail: Patrik.Ve[email protected]

Website: http://verstreken.vib.be/

EDUCATION AND PROFESSIONAL TRAINING

2003 Ph.D. in Developmental Biology, Baylor College of Medicine, Houston, TX

1998 Bio-Engineering - cell and gene technology (Engineering degree & Masters in

Science), University of Brussels (V.U.B.), Belgium

RESEARCH TOPICS

Molecular mechanisms of synaptic transmission

Molecular and genetic studies of Parkinsons disease

RESEARCH AREAS

We study neuronal communication in health and disease, by combining fruit fly genetics and

molecular biology with electrophysiological measurements of synaptic transmission and an array of

imaging strategies involving fluorescent markers and EM. Neurons in circuits communicate by

releasing transmitters from vesicles and to maintain communication, neurons depend on

evolutionary conserved mechanisms that ensure a continuous supply of synaptic vesicles to release

sites; these include endocytosis, vesicle mobilization and trafficking, calcium signalling, etc. Our long

term goal is to understand these molecular mechanisms of neuronal communication using

morphological and functional assays. The central importance of neuronal communication in the brain

is underscored by numerous psychiatric and neurological disorders, such as Parkinsons disease,

epilepsy and addiction arising from defects in neuronal function. Hence, our studies will not only help

elucidate mechanisms of normal but also of pathological brain function.

Our strategy is to use genome-wide genetic screens to identify components affecting synaptic

function to subsequently analyze the function of these genes in detail at live synapses. A prominent

set of genes we identified are either directly involved in Parkinsons disease or modulate phenotypes

linked to Parkinson related genes. We are now studying these genes in detail at the synapse not only

allowing us to gain insight into the ethiology of the neurological disease but also allowing us to gain

further insight into the mechanisms and concepts of synaptic function.

mailto:[email protected]://verstreken.vib.be/

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

32

MAJOR SCIENTIFIC AWARDS

ERC Starting Grant recipient, 2010

Francqui Docent recipient, 2009

Marie Curie Excellence Grant recipient, 2007

Finalist European Young Investigator award, 2006

1st place Baylor College of Medicine Department of Molecular and Human Genetics

publication/achievement award, 2005

1st place Sigma Xi Scientific Research Society dissertation award, 2004

Runner up 17th Larry Sandler Memorial Lecture, 45th Drosophila Research Conference, 2004

Post-doctoral fellow of the Belgian American Educational Foundation (BAEF) and Fellow of

the Brussels Hoover Foundation, 2003

1st place Beckmann Coulter Best platform presentation award, 2002

SELECTED PUBLICATIONS

1. Khong T.M., Habets R.L.P., Slabbaert J. and Verstreken P. (2010) Wiscott-Aldrich Syndrome

Protein is activated by PI(4,5)P2 to restrict neuromuscular junction growth in a pathway

parallel to BMP signaling. Proceedings of the National Academy of Sciences 107: 17379-

17384.

2. Verstreken P., Ohyama T., Haueter C., Habets R.L.P., Lin Y.Q., Swan L.E., Ly C.V., Venken K.J.,

De Camilli P. and Bellen H.J. (2009) Tweek, an evolutionarily conserved protein, is required

for synaptic vesicle recycling. Neuron 63: 203-215.

3. Choi C.M., Vilain S., Van Kelst S., Langen M., De Geest N., Yan J., Verstreken P. and Hassan

B.A. (2009) Conditional mutagenesis in Drosophila. Science 324: 54.

4. Morais V.A., Verstreken P., Rthig A., Smet J., Snellinx A., Haddad D.M., Mandemakers W.,

Van Coster R., Wurst W., Scorrano L. and De Strooper B. (2009) Parkinsons disease

mutations in PINK1 affect Complex I activity in mitochondria. EMBO Molecular Medicine 1:

99-101.

5. Kasprowicz J., Kuenen S., Habets R., Miskiewicz K., Smitz L. and Verstreken P. (2008)

Inactivation of clathrin heavy chain inhibits synaptic recycling but allows bulk membrane

uptake. Journal of Cell Biology 182: 1007-1016.

6. Romero E., Cha G.H., Verstreken P., Ly C.V., Hughes R.E., Bellen H.J. and Botas J. (2008)

Suppression of neurodegeneration and increased neurotransmission caused by expanded

full-length huntingtin accumulating in the cytoplasm. Neuron 57: 27-40.

7. Verstreken P., Ly C.V., Venken K.J.T., Koh T.W., Zhou Y. and Bellen H.J. (2005) Synaptic

mitochondria are critical for mobilization of the reserve pool vesicles at the Drosophila

neuromuscular junction. Neuron 47: 365-378.

8. Verstreken P., Kjaerulff O., Lloyd T.E., Atkinson R., Zhou Y., Meinertzhagen I.A. and Bellen H.J.

(2002) Endophilin mutations block clathrin-mediated endocytosis but not neurotransmitter

release. Cell 109: 101-112.

LEUVEN RESEARCH INSTITUTE FOR NEURODEGENERATIVE DISORDERS

33

MEMBERS

WIM ANNAERT, PH.D.

Contact address:

Center of Human Genetics

Laboratory of Membrane Trafficking

O&N1, Herestraat 49 bus 602

B-3000 Leuven

Tel: +32 16 33 05 20

Fax: +32 16 33 05 22

E-mail: [email protected]

EDUCATION AND PROFESSIONAL TRAINING

1993 PhD in Zoology, Faculty of Sciences, Univ. Antwerp

19941996 Postdoc Yale University, HHMI, (BAEF/Collenfellow/NIH), USA

19972002 FWOPostdoc Researcher, K.U.Leuven, Center for Human Genetics

2000present ZAP (10%) Independent Researcher, K.U.Leuven, Center for Human Genetics

2001present Group leader, VIB

2002present Professor BOFZAP, K.U.Leuven, Center for Human Genetics

2007present Associate Director of the Department of Molecular and Developmental Genetics, VIB

2008present Full professor, K.U.Leuven

RESEARCH TOPICS

Mechanisms of secretase sorting

Quality control of secretase assembly

Secretase independent functions

RESEARCH AREAS

Research of the Annaert lab is focused on the subcellular localization and regulatory sorting

mechanisms of key proteins involved in human neurodegenerative disease (Alzheimers disease) and

developmental disorders that include neurological abnormalities (congenital disorders of

glycosylation (CDG), monosomy 1p36). Specifically, we are interested in the secretase complex, a